BioCentury
ARTICLE | Clinical News

Cenderitide: Completed Phase II enrollment

April 13, 2015 7:00 AM UTC

Capricor completed enrollment of 14 patients in an open-label, dose-escalation, U.S. Phase II trial evaluating 0.5, 1, 2 and 3 ng/kg/min cenderitide given as a 48-hour continuous, subcutaneous infusio...